Association of cytotoxic T-lymphocyte antigen 4 genetic polymorphism, hepatitis C viral infection and B-cell non-Hodgkin lymphoma: an Egyptian study

References

• Song H, Tong D, Cha Z, et al. C-X-C chemokine receptor type 5 gene polymorphisms are associated with non-Hodgkin lymphoma. Mol Biol Rep 2012;39:8629–8635.
   PubMed Web of Science ®Google Scholar
• Muller AM, Ihorst G, Mertelsmann R, et al. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005;84:1–12.
   PubMed Web of Science ®Google Scholar
• Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica 2007;92: 960–969.
   PubMed Web of Science ®Google Scholar
• Alexander DD, Mink PJ, Adami H, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007;120:1–39.
   PubMed Web of Science ®Google Scholar
• Monne M, Piras G, Palmas A, et al. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin's lymphoma. Am J Hematol 2004;76:14–18.
   PubMed Web of Science ®Google Scholar
• Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611–618.
   PubMed Web of Science ®Google Scholar
• Appleman LJ, Berezovskaya A, Grass I, et al. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol 2002;164:144–151.
   Web of Science ®Google Scholar
• Scheipers P, Reiser H. Fas-independent death of activated CD4 (+) T lymphocytes induced by CTLA-4 crosslinking. Proc Natl Acad Sci USA 1998;95:10083–10088.
   PubMed Web of Science ®Google Scholar
• Puré E, Allison JP, Schreiber RD. Breaking down the barriers to cancer immunotherapy. Nat Immunol 2005;6:1207–1210.
   PubMedGoogle Scholar
• Vandenborre K, Van Gool SW, Kasran A, et al. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. Immunology 1999;98:413–421.
   PubMed Web of Science ®Google Scholar
• Sun T, Zhou Y, Yang M, et al. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 2008;68:7025–7034.
   PubMed Web of Science ®Google Scholar
• Danilovic DL, Mendes-Correa MC, Lima EU, et al. Correlations of CTLA-4 gene polymorphisms and hepatitis C chronic infection. Liver Int 2012;32:803–808.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Merli M, Volpetti S, et al. Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. Clin Dev Immunol 2012;2012:638185.
   PubMed Web of Science ®Google Scholar
• Varma S, Menon MC, Garg A, et al. Hepatitis C virus infection among patients with non-Hodgkin's 453 lymphoma in northern India. Hepatol Int 2011;5:688–692.
   PubMed Web of Science ®Google Scholar
• Farawela H, Khorshied M, Shaheen I, et al. The association between hepatitis C virus infection, genetic polymorphisms of oxidative stress genes and B-cell non-Hodgkin's lymphoma risk in Egypt. Infect Genet Evol 2012;12:1189–1194.
   PubMed Web of Science ®Google Scholar
• Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 2011;117:1792–1798.
   PubMed Web of Science ®Google Scholar
• Suarez F, Lortholary O, Hermine O, et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006;107:3034–3044.
   PubMed Web of Science ®Google Scholar
• Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;11:347:89–94.
   Web of Science ®Google Scholar
• De Re V, Caggiari L, Garziera M, et al. Molecular signature in HCV-positive lymphomas. Clin Dev Immunol 2012;2012:623465.
   PubMed Web of Science ®Google Scholar
• Yee LJ, Perez KA, Tang J, et al. Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J Infect Dis 2003; 187:1264–1271.
   PubMed Web of Science ®Google Scholar
• Nischalke HD, Vogel M, Mauss S, et al. The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(+) patients with acute and chronic hepatitis C virus co-infection. AIDS 2010;24, 24:2001–2007.
   Web of Science ®Google Scholar
• Schott E, Witt H, Pascu M, et al. Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease. Eur J Gastroenterol Hepatol 2007;19:947–951.
   PubMed Web of Science ®Google Scholar
• Cowgill K, Loffredo C, Eissa S, et al. Case control study of non-Hodgkin's lymphoma and hepatitis C virus infection in Egypt. Int J Epidemiol 2004;33:1034–1039.
   PubMed Web of Science ®Google Scholar
• Goldman L, Ezzat S, Mokhtar N, et al. Viral and non-viral risk factors for non-Hodgkin's lymphoma in Egypt: heterogeneity by histological and immunological subtypes. Cancer Causes Control 2009;20:981–987.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon; IARC Press; 2008.
   Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7: 1630–1636.
   PubMed Web of Science ®Google Scholar
• Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005;55:368–376.
   PubMed Web of Science ®Google Scholar
• Ban Y, Davies TF, Greenberg DA, et al. Analysis of the CTLA-4, CD28, and inducible costimulator (ICOS) genes in autoimmune thyroid disease. Genes Immun 2003;4:586–593.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Ihara K, Kanemistu S, et al. Association of CTLA-4 but not CD28 gene polymorphisms with systemic lupus erythematosis in the Japanese population. Rheumatology 2001;40:662–667.
   PubMed Web of Science ®Google Scholar
• Abo El-Khair SM, Metwali AA, Abd El-Maksoud M, et al. CTLA-4 gene polymorphism in relation to thyroid disorders in patients with chronic hepatitis C under interferon alpha therapy. Am J Biochem Biotechnol 2012;8:172–187.
   Google Scholar
• Piras G, Monne M, Uras A, et al. Genetic analysis of the 2q33 region containing CD28-CTLA4-ICOS genes: association with non-Hodgkin’s lymphoma. Br J Haematol 2005;129:784–790.
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364: 1195–1206.
   PubMed Web of Science ®Google Scholar